TD Asset Management
PBYI icon

TD Asset Management’s Puma Biotechnology PBYI Stock Holding History

TD Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-46,600
Closed -$486K – 1387
2020
Q2 		$486K Buy
46,600
+2,600
+6% +$26.9K ﹤0.01% 1220
2020
Q1 		$371K Buy
44,000
+9,300
+27% +$90.3K ﹤0.01% 1233
2019
Q4 		$304K Buy
34,700
+11,500
+50% +$95.2K ﹤0.01% 1314
2019
Q3 		$250K Sell
23,200
-1,600
-6% -$17.3K ﹤0.01% 1279
2019
Q2 		$315K Sell
24,800
-13,900
-36% -$320K ﹤0.01% 1243
2019
Q1 		$1.5M Buy
+38,700
New +$1.18M ﹤0.01% 966
2018
Q1 		– Sell
-33,362
Closed -$3.3M – 1360
2017
Q4 		$3.3M Sell
33,362
-78,617
-70% -$8.8M ﹤0.01% 771
2017
Q3 		$13.4M Buy
111,979
+31,481
+39% +$2.93M 0.02% 459
2017
Q2 		$7.04M Buy
80,498
+47,329
+143% +$2.65M 0.01% 599
2017
Q1 		$1.23M Buy
33,169
+12,398
+60% +$452K ﹤0.01% 990
2016
Q4 		$638K Sell
20,771
-4,800
-19% -$208K ﹤0.01% 1126
2016
Q3 		$1.72M Sell
25,571
-2,200
-8% -$111K ﹤0.01% 903
2016
Q2 		$827K Sell
27,771
-18,929
-41% -$592K ﹤0.01% 996
2016
Q1 		$1.37M Sell
46,700
-1,400
-3% -$63.3K ﹤0.01% 904
2015
Q4 		$3.77M Sell
48,100
-2,700
-5% -$212K 0.01% 730
2015
Q3 		$3.83M Sell
50,800
-6,800
-12% -$643K 0.01% 700
2015
Q2 		$6.72M Sell
57,600
-15,700
-21% -$2.84M 0.01% 604
2015
Q1 		$17.3M Buy
73,300
+14,500
+25% +$3.1M 0.03% 363
2014
Q4 		$11.1M Sell
58,800
-11,200
-16% -$2.48M 0.02% 460
2014
Q3 		$16.7M Buy
70,000
+5,900
+9% +$1.21M 0.03% 366
2014
Q2 		$4.23M Buy
64,100
+2,100
+3% +$149K 0.01% 699
2014
Q1 		$6.46M Buy
62,000
+3,900
+7% +$458K 0.01% 580
2013
Q4 		$6.01M Buy
58,100
+20,600
+55% +$1.21M 0.01% 578
2013
Q3 		$2.01M Buy
37,500
+1,900
+5% +$102K ﹤0.01% 800
2013
Q2 		$1.58M Buy
+35,600
New +$1.26M ﹤0.01% 796

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

TD Asset Management's PBYI Position: Q3 2020 in Review

TD Asset Management sold out of Puma Biotechnology (PBYI) in Q3 2020, closing a stake of 46,600 shares — an estimated $486K sold.

TD Asset Management first reported a position in PBYI in Q2 2013 and held it in 25 quarters. The position peaked at $17.3M in Q1 2015. 128 funds tracked by Wall St. Rank hold PBYI as of Q3 2020.

  • TD Asset Management reported no remaining Puma Biotechnology position as of Q3 2020 after selling out during the quarter.
  • TD Asset Management sold 46,600 Puma Biotechnology shares in Q3 2020, an estimated $486K.
  • TD Asset Management first reported a position in Puma Biotechnology in Q2 2013 and held it in 25 quarters.
  • TD Asset Management's Puma Biotechnology position peaked at $17.3M in Q1 2015.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2020.

Based on TD Asset Management's 13F filing for Q3 2020, filed 10 Nov 2020.